Sarcoidosis PBMC

In Stock Samples

Lot Number Condition Cell Count (M) Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
74428 Sarcoidosis 10M Caucasian 58 Male United States (US)
Albuterol, Rinvoq, merbetriq, Lefludimide, Gabapentin ventiline inhaler PRN exofenydine 180mg QD topomax 50mg PRN flomax 16g QD cyclobenzapine 10mg BID Rinvoq QD duoneb (nebulizer) QD cereba inhaler BID Pepcid singulair gabapentine 300mg TID colonzapan .5mg BID hydrochlorothiazide 25mg QD
3
58002 Sarcoidosis 10M Caucasian 65 Female United States (US)
dexalan 60mg QD hematryptaline 50mg BID alprazalan 0.5mg QD losartin 40mg QD brio 100mg/25 QD albuterol inhaler PRN diltyzan 240mg QD hydrocortozone 10mg BID hyoscyamine 0.125mg QD
7
56242 Sarcoidosis 3M Caucasian 65 Female United States (US)
dexalan 60mg QD hematryptaline 50mg BID alprazalan 0.5mg QD losartin 40mg QD brio 100mg/25 QD albuterol inhaler PRN diltyzan 240mg QD hydrocortozone 10mg BID hyoscyamine 0.125mg QD
1
56236 Sarcoidosis 10M Caucasian 62 Male United States (US)
mesalamine 1000 QD solatol 80mg BID eloquis 5mg BID prednisone 2.5mg BID methotrexate 15mg QIW synthroid .150mg QD (only 6 days/week) folic acid 1mg QD vitamins
3
56039 Sarcoidosis 10M Caucasian 22 Female United States (US)
zoloft, 100mg, QD Prednisone, 20mg, QD
2
56816 Sarcoidosis 10M Caucasian 60 Female United States (US)
prednisone QD humera QD
4
56331 Sarcoidosis 10M Caucasian 59 Male United States (US)
Remicade
2
55123 Sarcoidosis 10M Caucasian 71 Female United States (US)
Cell Cept
1
54650 Sarcoidosis 6M African American 49 Female United States (US) 1
55271 Sarcoidosis 10M Caucasian 63 Female United States (US)
ametryptoline 10mg BID atorvostatin 40mg QD eloquis 5mg BID intresto 25mg QD ferosenide 20mg QD gabapentine 300mg BID levothyroxine 125mcg QD metropolol50mg QD montelucus 1 tablet QD prednisone 5mg QD spironolactone 25mg QD
3

High-Quality Sarcoidosis PBMC for Research

Sarcoidosis Human PBMC samples products are sourced from donors clinically diagnosed with sarcoidosis and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on T cell activation, cytokine production, and transcriptomic profiles related to disease activity.

Product Features

  • Research Use Only (RUO), cryopreserved PBMCs
  • Clinically confirmed sarcoidosis donors
  • Available in cell counts ranging from 5 million to 2 billion
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • IRB-approved protocols and electronic informed consent
  • Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

  • Verified sarcoidosis diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Additional Sarcoidosis-specific data available upon request

Applications

  • Biomarker discovery and validation
  • Drug screening and therapeutic development
  • Immune pathway analysis in sarcoidosis pathophysiology
  • Transcriptomic and proteomic profiling

Quality and Compliance

  • IRB-approved collections and protocols
  • 21 CFR Part 11 – compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Shipping

Sarcoidosis PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 13–24 of 30 results

Do samples come with donor screening reports?

1 Answer

All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more here. https://sanguinebio.com/patient-reported-outcomes-pro-surveys-questionnaires/

YES – Certificate of analysis is available upon request.

Lead times vary from ready to ship inventory to prospective studies.

International shipping is available. We also work with a number of distributors. Contact us to discuss options at learnmore@sanguinebio.com.

We have several ordering methods. You can order directly online with a PO or credit card or contact us to have a sales specialist help with your order. https://sanguinebio.com/request-quote/

You can request a quote on this page or contact us at learnmore@sanguinebio.com. https://sanguinebio.com/request-quote/

NO – no minimum order requirements.

For bulk pricing inquiries, please contact: LearnMore@sanguinebio.com

YES – Fresh leukopaks can be delivered same day in select locations. Often, leukopaks are shipped same day as collection, thus arriving next day.

Contact learnmore@sanguinebio.com for current inventory. The website states “over 150 verified-conditions from ready-to-ship to prospective collections.” View our ready to ship products: https://sanguinebio.com/products/?pro_inventory=inventory

YES – Matched samples across multiple matrices are available, including synovial fluid are available.

1 2 3
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information